Integrated BioPharma (INBP) awards 140,000 stock options to Co-Chief Executive Officer

Rhea-AI Filing Summary

Integrated BioPharma Inc. reported a new equity award to its Co-Chief Executive Officer and director, Riva Sheppard. On 12/09/2025, Sheppard received a stock option to purchase 140,000 shares of common stock at an exercise price of $0.35 per share. The option has an expiration date of December 9, 2035 and vests in three equal annual installments, with the first tranche vesting on December 9, 2026. Following this grant, Sheppard holds 140,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIVA SHEPPARD

(Last) (First) (Middle)

C/O 225 LONG AVENUE

(Street)

HILLSIDE NJ 07205

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [ INBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.35	12/09/2025		A		140,000		(1)	12/09/2035	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026.

	/s/ Riva Sheppard	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Integrated BioPharma (INBP) disclose in this Form 4?

Integrated BioPharma disclosed that Co-Chief Executive Officer and director Riva Sheppard received a stock option grant covering 140,000 shares of common stock.

What is the exercise price and term of Riva Sheppard’s new stock options at INBP?

The stock option has an exercise price of $0.35 per share and an expiration date of December 9, 2035, giving it a 10-year term from the grant date.

How do the Integrated BioPharma (INBP) stock options granted to Riva Sheppard vest?

The option vests and becomes exercisable in three equal annual installments, with the first installment vesting on December 9, 2026, and the remaining installments vesting annually thereafter.

What role does the reporting person hold at Integrated BioPharma (INBP)?

The reporting person, Riva Sheppard, is disclosed as a director and an officer, serving as Co-Chief Executive Officer of Integrated BioPharma Inc.

How many derivative securities does Riva Sheppard own after this INBP transaction?

After the reported transaction, Riva Sheppard beneficially owns 140,000 derivative securities (stock options) in Integrated BioPharma, held with direct ownership.

Was the Integrated BioPharma (INBP) Form 4 filed for multiple insiders or just one?

The filing indicates that it is a Form filed by one reporting person, specifically Riva Sheppard.